Cargando…

Iguratimod: Novel Molecular Insights and a New csDMARD for Rheumatoid Arthritis, from Japan to the World

Iguratimod (IGU) is a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) routinely prescribed in Japan since 2012 to patients with rheumatoid arthritis (RA). Iguratimod acts directly on B cells by inhibiting the production of inflammatory cytokines (tumor necrosis factor-α, inter...

Descripción completa

Detalles Bibliográficos
Autor principal:	Nozaki, Yuji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160848/ https://www.ncbi.nlm.nih.gov/pubmed/34065413 http://dx.doi.org/10.3390/life11050457

Ejemplares similares

Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2023)

Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics
por: Kremer, Joel M, et al.
Publicado: (2018)

Female reproductive status and exogenous sex hormone use in rheumatoid arthritis patients treated with tocilizumab and csDMARDs
por: Daraghmeh, Dala N, et al.
Publicado: (2022)

Dynamic Characteristics and Predictive Profile of Glucocorticoids Withdrawal in Rheumatoid Arthritis Patients Commencing Glucocorticoids with csDMARD: A Real-World Experience
por: Xie, Wenhui, et al.
Publicado: (2023)

Abatacept is Efficacious in the Treatment of Older Patients with csDMARD-Refractory Rheumatoid Arthritis: A Prospective, Multicenter, Observational Study
por: Muraoka, Sei, et al.
Publicado: (2021)

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients
por: Humby, Frances, et al.
Publicado: (2019)

First-line csDMARD monotherapy drug retention in psoriatic arthritis: methotrexate outperforms sulfasalazine
por: Jacobs, Marleen E, et al.
Publicado: (2020)

Investigating the safety and compliance of using csDMARDs in rheumatoid arthritis treatment through face-to-face interviews: a cross-sectional study in China
por: Sun, Jiaying, et al.
Publicado: (2020)

JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy
por: Gremese, Elisa, et al.
Publicado: (2019)

A Blood Protein Signature Stratifies Clinical Response to csDMARD Therapy in Pediatric Uveitis
por: Wennink, Roos A. W., et al.
Publicado: (2022)

Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis
por: Hernández-Breijo, Borja, et al.
Publicado: (2019)

Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies
por: Genovese, Mark C., et al.
Publicado: (2020)

The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRA registry
por: Skácelová, Martina, et al.
Publicado: (2022)

Impact of csDMARDs adherence on clinical remission in patients with new-onset inflammatory arthritis: a prospective cohort study from the ELECTRA database
por: Zanetti, Anna, et al.
Publicado: (2023)

Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (HR-pQCT), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) plus denosumab vs csDMARD therapy alone: an open-label, randomized, parallel-group study
por: Iwamoto, Naoki, et al.
Publicado: (2022)

Establishment and verification of a nomogram and a preliminary study on predicting the clinical response of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in rheumatoid arthritis patients
por: Sun, Zhijian, et al.
Publicado: (2022)

Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial
por: Väänänen, Tuija, et al.
Publicado: (2017)

A national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors
por: İNANÇ, Güzide Nevsun, et al.
Publicado: (2023)

Serum matrix metalloproteinase 3 levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs in patients with rheumatoid arthritis
por: Tokai, Nao, et al.
Publicado: (2018)

Correction: Serum matrix metalloproteinase 3 levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs in patients with rheumatoid arthritis
por: Tokai, Nao, et al.
Publicado: (2019)

Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid Arthritis
por: Li, Jiangtao, et al.
Publicado: (2013)

Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape
por: Xie, Sisi, et al.
Publicado: (2020)

The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care
por: Inoue, Asuka, et al.
Publicado: (2020)

Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration
por: Lindström, Ulf, et al.
Publicado: (2021)

Corrigendum: Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape
por: Xie, Sisi, et al.
Publicado: (2020)

Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol
por: Mueller, Ruediger B., et al.
Publicado: (2019)

Influence of Iguratimod on Bone Metabolism in Patients with Rheumatoid Arthritis: A Meta-analysis
por: Deng, Li, et al.
Publicado: (2022)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
por: Mysler, Eduardo, et al.
Publicado: (2021)

Effectiveness and safety of iguratimod treatment in patients with active rheumatoid arthritis in Chinese: A nationwide, prospective real-world study
por: Mu, Rong, et al.
Publicado: (2021)

Conflict between efficacy and economy in rheumatoid arthritis treatment: Iguratimod is found at a compromise
por: Tanaka, Masao
Publicado: (2021)

Multidrug resistance proteins and DMARD efficacy in rheumatoid arthritis
por: Jansen, G, et al.
Publicado: (2004)

Treatment of Rheumatoid Arthritis with Biologic DMARDS (Rituximab and Etanercept)
por: Gashi, Afrim A., et al.
Publicado: (2014)

Delayed conventional DMARDs therapy is effective in Rheumatoid Arthritis
por: Ahsan, Tasnim, et al.
Publicado: (2017)

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
por: Riley, Thomas R, et al.
Publicado: (2021)

Iguratimod Inhibits the Aggressiveness of Rheumatoid Fibroblast-Like Synoviocytes
por: Lin, Jin, et al.
Publicado: (2019)

Regulatory Effect of Iguratimod on the Balance of Th Subsets and Inhibition of Inflammatory Cytokines in Patients with Rheumatoid Arthritis
por: Xu, Yunzhi, et al.
Publicado: (2015)

Real-world comparative effectiveness of bDMARDs and JAK inhibitors in elderly patients with rheumatoid arthritis
por: Temmoku, Jumpei, et al.
Publicado: (2022)

Biomarkers to Predict DMARDs Efficacy and Adverse Effect in Rheumatoid Arthritis
por: Wei, Kai, et al.
Publicado: (2022)

Rheumatoid Arthritis and Malignancy: What Should We Do With DMARDs?
por: Jeon, Chan Hong
Publicado: (2022)

Real World Experience of Disease Activity in Patients With Rheumatoid Arthritis and Response to Treatment With Varios Biologic DMARDs
por: Boyadzhieva, Vladimira, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_flabgo2u3n29qgvcr14jnrt8kj